Tempus AI, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on the stock and has a $80.00 price target.
Claim 30% Off TipRanks
New trading tool for TEM bullsKyle Mikson CFA has given his Buy rating due to a combination of factors, including Tempus AI’s strong top-line momentum and reaffirmed growth outlook. The company delivered robust fourth-quarter revenue, led by triple-digit Diagnostics growth and particularly solid expansion in Oncology and Hereditary testing volumes, while reiterating its 2026 sales and profitability targets that imply sustained, above-market growth.
Mikson also highlights the accelerating contribution from Data and Applications, where rising pharma demand, expanding contracts, and growing use of AI-enabled tools are deepening Tempus’s competitive moat. With multiple upcoming catalysts in oncology, MRD, rare disease testing, and AI applications, he views Tempus as a leader in AI-driven precision medicine whose current valuation does not yet capture its long-term growth potential.
In another report released today, Needham also reiterated a Buy rating on the stock with a $75.00 price target.
Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEM in relation to earlier this year.